Omada Health (NASDAQ:OMDA) CEO Sean Duffy Sells 2,800 Shares of Stock

Omada Health, Inc. (NASDAQ:OMDA) CEO Sean Duffy sold 2,800 shares of the company’s stock in a transaction on Wednesday, June 24th. The shares were sold at an average price of $19.01, for a total transaction of $53,228.00. Following the sale, the chief executive officer directly owned 409,061 shares in the company, valued at approximately $7,776,249.61. The trade was a 0.68% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Omada Health Stock Up 10.5%

OMDA stock opened at $20.89 on Friday. Omada Health, Inc. has a 52 week low of $10.28 and a 52 week high of $26.92. The firm has a market capitalization of $1.24 billion and a P/E ratio of -77.37. The company has a fifty day simple moving average of $16.51 and a two-hundred day simple moving average of $14.85.

Omada Health (NASDAQ:OMDA) last posted its earnings results on Thursday, May 7th. The company reported ($0.05) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.03. The firm had revenue of $78.05 million for the quarter. Omada Health had a negative net margin of 2.22% and a negative return on equity of 1.82%. As a group, analysts anticipate that Omada Health, Inc. will post -0.01 EPS for the current year.

Institutional Trading of Omada Health

Institutional investors have recently added to or reduced their stakes in the company. Universal Beteiligungs und Servicegesellschaft mbH bought a new position in shares of Omada Health during the fourth quarter valued at approximately $1,222,000. Divisadero Street Capital Management LP bought a new stake in shares of Omada Health during the 3rd quarter worth approximately $30,510,000. a16z Perennial Management L.P. purchased a new position in Omada Health during the 4th quarter valued at $2,480,000. Madryn Asset Management LP purchased a new position in Omada Health during the 4th quarter valued at $9,212,000. Finally, Independent Advisor Alliance bought a new position in Omada Health in the 4th quarter valued at $717,000.

Analyst Ratings Changes

A number of equities research analysts have issued reports on OMDA shares. Barclays upped their price objective on Omada Health from $18.00 to $20.00 and gave the company an “overweight” rating in a research report on Friday, May 8th. Canaccord Genuity Group set a $24.00 target price on Omada Health in a report on Friday, May 8th. Wells Fargo & Company boosted their target price on Omada Health from $17.00 to $18.00 and gave the company an “equal weight” rating in a research report on Friday, May 8th. Wall Street Zen upgraded Omada Health from a “hold” rating to a “buy” rating in a report on Saturday. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Omada Health in a research report on Thursday, June 4th. Ten investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $22.91.

Omada Health Company Profile

Omada Health is a digital health company that specializes in the prevention and management of chronic conditions through personalized, technology-driven programs. The company’s platform combines data analytics, behavioral science and human coaching to support individuals at risk for or living with conditions such as prediabetes, type 2 diabetes, hypertension and musculoskeletal disorders. Participants access the program via a mobile app or web portal, where they receive tailored curriculum, feedback on health metrics and ongoing virtual coaching.

In addition to its core disease-management offerings, Omada Health has expanded its services to include mental health support and digital therapeutics for weight management.